Fig. 1: DYRK2 is highly expressed in PCa. | Nature Communications

Fig. 1: DYRK2 is highly expressed in PCa.

From: Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer

Fig. 1

a–c Comparison of DYRK2 expression between tumor (red, n = 51) and normal (gray, n = 51) tissues (a), high (red, n = 345) and intermediate (blue, n = 152) risk PCa patients (b), age ≤65 (blue, n = 354) or > 65 (yellow, n = 143) PCa patients (c) in TCGA database. FRKM: fragment per killo million. The whiskers of boxplot represent the quantile percentile, from bottom to top are minima, 25%, median, 75%, and maxima respectively. Two-tailed Student’s t test was applied without adjustment for multiple comparisons (false discovery rate, FDR). d Kaplan–Meier survival plot of high (red line, n = 246) and low (blue line, n = 246) DYRK2 expression PCa patients. Log-rank test, P = 0.015. e, f Analysis of DYRK2 expression in three PCa patients. DYRK2 mRNA level (e) and immunohistochemical analysis of DYRK2 expression (f) in tumor and normal tissues. Unpaired two-tailed Student’s t test. Error bar, mean ± SD, n = 3. g DYRK2 protein levels in different PCa cell lines. Normal prostate epithelial cell RWPE-1 was used as the control. Source data are provided as a Source Data file.

Back to article page